Targeted magnetic resonance imaging with intraperitoneal and intravenous streptavidin (SA)-DTPA-Gd: a comparative study in tumor-bearing nude mice.
- Author:
Jing YE
1
;
Yi-kai XU
;
Xian LIU
;
Guo-shi LÜ
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; diagnosis; metabolism; Animals; Antibodies, Monoclonal; administration & dosage; pharmacokinetics; Cell Line, Tumor; Colorectal Neoplasms; diagnosis; metabolism; Contrast Media; administration & dosage; Gadolinium DTPA; administration & dosage; pharmacokinetics; Humans; Injections, Intraperitoneal; Injections, Intravenous; Magnetic Resonance Imaging; methods; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; diagnosis; metabolism; Reproducibility of Results; Sensitivity and Specificity; Streptavidin; administration & dosage; pharmacokinetics; Transplantation, Heterologous
- From: Journal of Southern Medical University 2006;26(2):139-143
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo investigate the effect of streptavidin (SA)-DTPA-Gd after intraperitoneal and intravenous administration for tumor enhancement in targeted magnetic resonance imaging (MRI).
METHODSBiotinylated monoclonal antibody CL3 (600 microg) was intravenously injected into 12 BALB/c nude mice with subcutaneous inoculation of LoVo cells, followed by administration of 80 microg avidin as the chaser 24 h later and then SA-DTPA-Gd was injected intravenously or intraperitoneally after another 30 min. MRI was performed before and 20, 60 min and 3, 6, 9, 12 h after the injection of the contrast agents, and the MR signal intensity of the tumor and liver was determined.
RESULTThe maximum enhancement ratio of the tumor was 70.2% in the intravenous injection group and 46.4% in the intraperitoneal group, showing significant difference between them. The maximal enhancement rate of the liver was 23.7% in the intraperitoneal group and 20.4% in the intravenous group, showing no significant difference.
CONCLUSIONMR targeted imaging with biotinylated monoclonal antibody CL3 and SA-DTPA-Gd has specific enhancement effect. Higher blood level of SA-DTPA-Gd in the intravenous group facilitates the tumor enhancement in MRI in subcutaneous tumor model.
